A retrospective study to determine clinical factors in patients with mRCC who received their first cycle of nivolumab and ipilimumab
Latest Information Update: 21 Sep 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 21 Sep 2021 New trial record